myNEO Therapeutics

myNEO Therapeutics is a Belgian biotechnology company founded in 2018, specializing in AI-driven neoantigen discovery and cancer immunotherapy. Its ImmunoEngine platform combines immunology expertise with AI to support personalized neoantigen discovery, mRNA codon optimization, ADA risk prediction, and multi-epitope construct design for vaccine developers, biologics innovators, and pharma partners.

myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team. To date, myNEO has achieved several pivotal milestones including development of state-of-the-art antigen prediction algorithms, discovery of novel dark antigen targets called camyotopes, (co-)development of novel immunotherapeutics products leading to 3 separate programs executing successful IND/CTA filings in 2025, publication of high-impact scientific papers, ISO and regulatory approval for clinical use of technology, securing valuable intellectual property with multiple patents, and receiving several prestigious awards.

1. 1AI-Powered Neoantigen & Immunotherapy Discovery | myNEOmyneotx.com
2. 2About Us — myNEO Therapeutics, Ghent Belgiummyneotx.com
3. 3Careers — Join myNEO Therapeutics in Ghent, Belgiummyneotx.com
4. 4myNEO Therapeuticswikidata.org